US4771051A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3-substituted-4,5-dihydro-5-oxo imidazoquinazolines, their preparation, and their use in treating benzodiazepin receptor-related ailments
Assignee: Novo Nordisk AS
•
Filing: 1986-09-26
•
Granted: 1988-09-13
•
Expires: 2006-09-26
Abstract
Abstract New heterocyclic compounds having the general formula ##STR1## wherein X is ##STR2## or CO 2 R' wherein R' is C 1-6 -alkyl, C 3-7 -cycloalkyl, or C 3-7 -cycloalkylmethyl, R 6 and R 7 independently are hydrogen, halogen, alkoxy, or trifluoromethyl, and R" is hydrogen, C 1-6 -alkyl, or C 3-7 -cycloalkyl. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.
Inventors
- 👤 Frank Watjen
- 👤 Mogens Engelstoft
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 16:19
CPC Classifications
C; C07; C07D; C07D271/00; C07D271/02; C07D271/06; C07D487/00; C07D487/02; C07D487/04; C07D513/00; C07D513/02; C07D513/04
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
51 words
Heterocyclic quinazoline compounds having the formula ##STR21## wherein X is ##STR22## or CO 2 R' wherein R' is C 1-6 -alkyl, C 3-7 -cycloalkyl, or C 3-7 -cycloalkylmethyl, R 6 and R 7 independently are hydrogen, halogen, alkoxy, or fluoromethyl, and R" is hydrogen, C 1-6 -alkyl, or C 3-7 -cycloalkyl.
Claim 2
Dependent Claim
51 words
Heterocyclic quinazoline compounds having the formula ##STR21## wherein X is ##STR22## or CO 2 R' wherein R' is C 1-6 -alkyl, C 3-7 -cycloalkyl, or C 3-7 -cycloalkylmethyl, R 6 and R 7 independently are hydrogen, halogen, alkoxy, or fluoromethyl, and R" is hydrogen, C 1-6 -alkyl, or C 3-7 -cycloalkyl.
Claim 3
Dependent Claim
8 words
A compound of claim 1 which is 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4-methyl-5-oxo-6-chloro-imidazo(1,5-a)quinazoline.
Claim 4
Dependent Claim
45 words
A pharmaceutical composition suitable for use in the treatment of a central nervous system ailment related to the benzodiazepin receptors comprising an amount of a compound of claim 1 which is effective for the alleviation of such disorder together with a pharmaceutically-acceptable carrier or diluent.
Claim 5
Dependent Claim
22 words
A pharmaceutical composition according to claim 3 in the form of an oral dosage unit containing 1-100 mg of the active compound.
Claim 6
Dependent Claim
47 words
A method of treating a central nervous system ailment related to the benzodiazepin receptors in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound of claim 1 which is effective for the alleviation of such ailment.
Claim 7
Dependent Claim
67 words
A method of treating a central nervous system ailment related to the benzodiazepin receptors in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound of claim 1 which is effective for the alleviation of such ailment in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically-acceptable carrier or diluent.
References Cited (Backward Citations)
US3600390A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-09-13 | 1992-03-14 | 1992-09-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-09-13 | 1996-03-14 | 1996-09-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-09-13 | 2000-03-14 | 2000-09-13 | $7700.00 | Window Closed / Lapsed |